Literature DB >> 15279847

From magic bullets to designed multiple ligands.

Richard Morphy1, Corinne Kay, Zoran Rankovic.   

Abstract

Increasingly, it is being recognised that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand. Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes. A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile. An analysis of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compounds.

Mesh:

Substances:

Year:  2004        PMID: 15279847     DOI: 10.1016/S1359-6446(04)03163-0

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  119 in total

1.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

2.  Drug discovery in a multidimensional world: systems, patterns, and networks.

Authors:  Joel T Dudley; Eric Schadt; Marina Sirota; Atul J Butte; Euan Ashley
Journal:  J Cardiovasc Transl Res       Date:  2010-07-31       Impact factor: 4.132

3.  Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Authors:  Lena Hefke; Kerstin Hiesinger; W Felix Zhu; Jan S Kramer; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

4.  New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.

Authors:  John L Neumeyer; Xuemei Peng; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Severo Salvadori; Claudio Trapella; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

5.  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

6.  N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.

Authors:  Jing Tang; Kasthuraiah Maddali; Christine D Dreis; Yuk Y Sham; Robert Vince; Yves Pommier; Zhengqiang Wang
Journal:  ACS Med Chem Lett       Date:  2011-01       Impact factor: 4.345

7.  How many drugs are catecholics.

Authors:  Da-Peng Yang; Hong-Fang Ji; Guang-Yan Tang; Wei Ren; Hong-Yu Zhang
Journal:  Molecules       Date:  2007-04-30       Impact factor: 4.411

8.  Identification of diaryl 5-amino-1,2,4-oxadiazoles as tubulin inhibitors: the special case of 3-(2-fluorophenyl)-5-(4-methoxyphenyl)amino-1,2,4-oxadiazole.

Authors:  Andrei A Gakh; Andrey V Sosnov; Mikhail Krasavin; Tam Luong Nguyen; Ernest Hamel
Journal:  Bioorg Med Chem Lett       Date:  2013-01-11       Impact factor: 2.823

Review 9.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

Review 10.  Structure and Anti-HIV Activity of Betulinic Acid Analogues.

Authors:  Qiu-Xia Huang; Hong-Fei Chen; Xing-Rui Luo; Yin-Xiang Zhang; Xu Yao; Xing Zheng
Journal:  Curr Med Sci       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.